Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Human Menopausal Gonadotropin→

Human Menopausal Gonadotropin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
61489-71-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Gonadotropin preparationurinary human FSH/LH (menotrophin)
Mechanism of action
Provides follicle-stimulating hormone (FSH) and luteinising hormone (LH) activity. FSH stimulates ovarian follicular development and granulosa-cell function, while LH supports theca-cell androgen production and, with appropriate stimulation, ovulation; in men, gonadotropin activity supports spermatogenesis through Sertoli and Leydig cell signalling.
Indications / reported uses
  • Controlled ovarian stimulation for assisted reproductive technology and ovulation induction in women with anovulation or inadequate gonadotropin response.
  • Stimulation of spermatogenesis in selected men with hypogonadotropic hypogonadism, usually in combination with hCG.

Sources: https://www.medicines.org.uk/emc/product/4595/smpc · https://www.ema.europa.eu/en/medicines/human/EPAR/menopur · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Human Menopausal Gonadotropin Environmental Risk Assessment (ERA) (the Human Menopausal Gonadotropin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.